Who
Kathleen Ford
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Kura Oncology.
In numbers
- Trades disclosed
- 46
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $1.7M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 9 Aug 2019
- Last trade
- 29 Sep 2026
- Last filed
- 29 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $39K3,668 at $10.75 | filing |
| 29 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $39K3,668 at $10.75 | filing |
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $72K6,906 at $10.50 | filing |
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $73K6,906 at $10.50 | filing |
| 19 May 2026filed 20 May 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $20K2,257 at $9.08 | filing |
| 19 May 2026filed 20 May 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $20K2,257 at $9.08 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $15K1,813 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $15K1,813 at $8.46 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 14 Nov 2025filed 14 Nov 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $77K6,902 at $11.18 | filing |
| 13 Nov 2025filed 14 Nov 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —48,900 at $0.00 | filing |
| 29 Sep 2025filed 29 Sep 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $62K6,892 at $8.94 | filing |
| 27 Sep 2025filed 29 Sep 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —48,900 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $9,7841,558 at $6.28 | filing |
| 28 Jan 2025filed 28 Jan 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $14K1,817 at $7.87 | filing |
| 2 Jan 2025filed 6 Jan 2025 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —185,000 at $0.00 | filing |
| 18 Nov 2024filed 19 Nov 2024 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $8,432526 at $16.03 | filing |
News
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesKURA · manilatimes.net · 13 Oct 2026Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in DiabetesKURA · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Kathleen Ford; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.